Peer-influenced content. Sources you trust. No registration required. This is HCN.

Anlotinib Prolongs OS in RAS, KRAS, BRAF-Wildtype Metastatic CRC

According to research presented at the virtual ASCO GI Cancers Symposium from the phase 3 ALTER0703 trial, anlotinib was beneficial in Chinese patients with refractory metastatic colorectal cancer (CRC), with particular overall survival (OS) improvement – the primary endpoint – among patients with RAS/KRAS/BRAF-wildtype.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form